Engineered Tumor-Specific T Cells May Help Relapsed Hodgkin Lymphoma Patients
A recent study found that Hodgkin lymphoma patients with active disease achieved clinical responses with tumor-specific T cells that were genetically modified to be rendered resistant to transforming growth factor beta, a cytokine expressed by most human cancers.
Source: CancerNetwork - Category: Cancer & Oncology Authors: John Schieszer Tags: Hematologic Malignancies Hodgkin Lymphoma News Source Type: news
More News: Cancer | Cancer & Oncology | Genetics | Hematology | Hodgkin's Disease | Lymphoma | Study